ArticleCancer medicine2024

Correction to: Initial ribociclib plus endocrine therapy for HR+/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study.

No numbers read from the abstract.

Not cited yet